8-K: Kalaris Therapeutics Sets August 12 for 2025 Annual Meeting, Announces Shareholder Proposal Deadlines

Kalaris Therapeutics, Inc. has announced its 2025 annual meeting of stockholders will be held on August 12, 2025, with specific deadlines set for shareholder proposals and director nominations due to the change in meeting date.

Summary

• Kalaris Therapeutics, Inc. (the "Company") has established August 12, 2025, as the date for its 2025 annual meeting of stockholders (the "2025 Annual Meeting").
• The date of the 2025 Annual Meeting will change by more than 30 calendar days from the anniversary date of the Company's 2024 annual meeting.
• Due to this change, the deadline for stockholder proposals submitted pursuant to Rule 14a-8 for inclusion in the Company's proxy materials is June 30, 2025.
• Stockholders wishing to nominate a director or propose matters to be considered at the 2025 Annual Meeting under the Company's Amended and Restated By-laws must submit timely notice by June 30, 2025.
• The meeting date is delayed by more than 60 days from the first anniversary of the Company's 2024 annual meeting of stockholders.

Sentiment

Score: 5

Explanation: The document is neutral, providing factual information about the scheduling of the annual meeting and associated deadlines without indicating positive or negative financial or operational performance.

Risks

• Stockholder proposals and director nominations may be omitted if they do not comply with the Company's Amended and Restated By-laws and the rules of the Securities and Exchange Commission regarding the inclusion of stockholder proposals in proxy materials.

Future Outlook

The Company plans to publish additional details regarding the exact time, location, and matters to be voted on at the 2025 Annual Meeting in its upcoming proxy statement.

Management Comments

• The Company has determined [June 30, 2025] to be a reasonable time before the Company's proxy materials are due to be printed and sent.

Industry Context

This filing is a routine procedural announcement common among publicly traded companies, detailing the scheduling of their annual shareholder meeting and associated deadlines for shareholder participation, which is a standard corporate governance practice.

Stakeholder Impact

• Shareholders are impacted by the new meeting date and the deadlines for submitting proposals and director nominations, requiring them to adhere to the new schedule for participation.

Next Steps

• The Company will publish additional details regarding the exact time, location, and matters to be voted on at the 2025 Annual Meeting in its proxy statement.

Key Dates

Keywords

Kalaris Therapeutics, KLRS, Annual Meeting, Shareholder Meeting, Proxy Statement, Stockholder Proposals, Director Nominations, SEC Filing, 8-K, Corporate Governance